Back to top
more

uniQure (QURE)

(Real Time Quote from BATS)

$13.59 USD

13.59
173,118

-0.18 (-1.31%)

Updated Aug 5, 2025 11:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 12.50% and 97.47%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

uniQure (QURE) Up on Safety Data From Huntington's Disease Study

by Zacks Equity Research

uniQure (QURE) posts safety and biomarker data from the 10 patients enrolled in the lower-dose cohort of its ongoing phase I/II study evaluating AMT-130 for treating Huntington's disease.

Zacks Equity Research

uniQure (QURE) Moves 27% Higher: Will This Strength Last?

by Zacks Equity Research

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of -49.25% and 96.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

M&As in Spotlight With GSK Announcement: 3 Biotechs in Focus

by Zacks Equity Research

We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates for a potential takeover in 2022.

Zacks Equity Research

uniQure (QURE) Stock Jumps 8.1%: Will It Continue to Soar?

by Zacks Equity Research

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

uniQure (QURE) Moves 5% Higher: Will This Strength Last?

by Zacks Equity Research

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

UniQure (QURE) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 123.61% and 129.68%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

After Plunging 33.5% in 4 Weeks, Here's Why the Trend Might Reverse for uniQure (QURE)

by Zacks Equity Research

The heavy selling pressure might have exhausted for uniQure (QURE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

uniQure (QURE) Upgraded to Buy: Here's Why

by Zacks Equity Research

uniQure (QURE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

uniQure (QURE) Falls on Data From Huntington's Disease Study

by Zacks Equity Research

uniQure (QURE) reports initial data on the first four patients enrolled in the lower-dose cohort of its ongoing phase I/II clinical trial of AMT-130 for treating Huntington's disease.

Zacks Equity Research

UniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 21.00% and -46.24%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will uniQure (QURE) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

by Kinjel Shah

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

Zacks Equity Research

UniQure (QURE) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 198.60% and 118.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

UniQure (QURE) to Report Q2 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of -2.25% and -89.98%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: uniQure (QURE) Q1 Earnings Expected to Decline

by Zacks Equity Research

UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Strength Seen in uniQure (QURE): Can Its 8.3% Jump Turn into More Strength?

by Zacks Equity Research

uniQure (QURE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

UniQure (QURE) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 98.72% and -59.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

UniQure (QURE) to Report Q4 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals

Zacks Equity Research

4 Biotechs That Could Be Potential Acquisition Targets in 2021

by Zacks Equity Research

We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.

Zacks Equity Research

Pfizer (PFE) Begins Phase III Study on Hemophilia Candidate

by Zacks Equity Research

Pfizer (PFE) doses the first participant in the late-stage BASIS study, currently investigating marstacimab to address severe hemophilia A or B with or without inhibitors.

Zacks Equity Research

UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of -171.18% and -98.82%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?